Profusa (NASDAQ: PFSA) has announced that Yann Gouëffic, MD, PhD, professor of vascular surgery in the Vascular Center at Groupe Hospitalier Paris Saint Joseph, Paris, France will adopt the company’s Lumee oxygen monitoring technology in his practice and in clinical studies, advancing application of Lumee for home monitoring.
Pr. Gouëffic is a leading surgeon in the field of critical limb threatening ischemia (CLTI).
In a statement, Pr. Gouëffic commented, “My practice, in addition to those of my affiliates, treats a meaningful number of CLTI cases in France and I believe Profusa’s Lumee technology to be a game changer in our patient care program and a true advancement clinical disease governance. Real-time oxygen monitoring data for patients suffering from CLTI, while critical during surgery is equally as important during recovery at home. Given the large clinical need, I believe offering Lumee to our patients will result in improved outcomes.”
Ben Hwang, PhD, chairman and CEO of Profusa, remarked, “Our Lumee oxygen monitoring system continues to be validated with the steady addition of new surgeon customers to our network. We warmly welcome Pr. Gouëffic and look forward to advancing vascular disease management with our commercial and clinical collaboration. We are also excited to serve Pr. Gouëffic’s affiliates, which all combined, account for approximately 8% of CLTI cases in France. We believe we provide a differentiated, real time biochemistry monitoring platform technology for use at the clinic and at home, and are focused on serving a large endovascular market need, estimated at over 300,000 procedures a year in Europe.”
